311 related articles for article (PubMed ID: 38612768)
21. Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer.
Xiang XS; Li PC; Wang WQ; Liu L
Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188676. PubMed ID: 35016922
[TBL] [Abstract][Full Text] [Related]
22. The biological underpinnings of therapeutic resistance in pancreatic cancer.
Beatty GL; Werba G; Lyssiotis CA; Simeone DM
Genes Dev; 2021 Jul; 35(13-14):940-962. PubMed ID: 34117095
[TBL] [Abstract][Full Text] [Related]
23. Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis.
Chen L; Xu X; Wen X; Xu S; Wang L; Lu W; Jiang M; Huang J; Yang D; Wang J; Zheng M; Zhou XZ; Lu KP; Liu H
Cancer Sci; 2019 Aug; 110(8):2442-2455. PubMed ID: 31148345
[TBL] [Abstract][Full Text] [Related]
24. Involvement of epithelial to mesenchymal transition in the development of pancreatic ductal adenocarcinoma.
Satoh K; Hamada S; Shimosegawa T
J Gastroenterol; 2015 Feb; 50(2):140-6. PubMed ID: 25216997
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype.
Orben F; Lankes K; Schneeweis C; Hassan Z; Jakubowsky H; Krauß L; Boniolo F; Schneider C; Schäfer A; Murr J; Schlag C; Kong B; Öllinger R; Wang C; Beyer G; Mahajan UM; Xue Y; Mayerle J; Schmid RM; Kuster B; Rad R; Braun CJ; Wirth M; Reichert M; Saur D; Schneider G
JCI Insight; 2022 May; 7(10):. PubMed ID: 35439169
[TBL] [Abstract][Full Text] [Related]
26. Protein arginine methylation of non-histone proteins and its role in diseases.
Wei H; Mundade R; Lange KC; Lu T
Cell Cycle; 2014; 13(1):32-41. PubMed ID: 24296620
[TBL] [Abstract][Full Text] [Related]
27. Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.
Kumar S; Singh SK; Srivastava P; Suresh S; Rana B; Rana A
Adv Cancer Res; 2023; 159():113-143. PubMed ID: 37268394
[TBL] [Abstract][Full Text] [Related]
28. Precision treatment of pancreatic ductal adenocarcinoma.
Wei H; Ren H
Cancer Lett; 2024 Mar; 585():216636. PubMed ID: 38278471
[TBL] [Abstract][Full Text] [Related]
29. METTL3 suppresses pancreatic ductal adenocarcinoma progression through activating endogenous dsRNA-induced anti-tumor immunity.
Zhu L; Li B; Li R; Hu L; Zhang Y; Zhang Z; Jiang S; Zhang X
Cell Oncol (Dordr); 2023 Oct; 46(5):1529-1541. PubMed ID: 37178367
[TBL] [Abstract][Full Text] [Related]
30. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
Okada Y; Takahashi N; Takayama T; Goel A
Carcinogenesis; 2021 Apr; 42(4):546-556. PubMed ID: 33624791
[TBL] [Abstract][Full Text] [Related]
31. Glycogen synthase kinase-3β: a novel therapeutic target for pancreatic cancer.
Ding L; Billadeau DD
Expert Opin Ther Targets; 2020 May; 24(5):417-426. PubMed ID: 32178549
[No Abstract] [Full Text] [Related]
32. Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers.
Prabhu L; Wei H; Chen L; Demir Ö; Sandusky G; Sun E; Wang J; Mo J; Zeng L; Fishel M; Safa A; Amaro R; Korc M; Zhang ZY; Lu T
Oncotarget; 2017 Jun; 8(25):39963-39977. PubMed ID: 28591716
[TBL] [Abstract][Full Text] [Related]
33. Regulation of pancreatic cancer therapy resistance by chemokines.
Gautam SK; Basu S; Aithal A; Dwivedi NV; Gulati M; Jain M
Semin Cancer Biol; 2022 Nov; 86(Pt 2):69-80. PubMed ID: 36064086
[TBL] [Abstract][Full Text] [Related]
34. The macromolecular complexes of histones affect protein arginine methyltransferase activities.
Fulton MD; Cao M; Ho MC; Zhao X; Zheng YG
J Biol Chem; 2021 Oct; 297(4):101123. PubMed ID: 34492270
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?
Ciernikova S; Earl J; García Bermejo ML; Stevurkova V; Carrato A; Smolkova B
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32521716
[TBL] [Abstract][Full Text] [Related]
36. The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma.
Michael Traeger M; Rehkaemper J; Ullerich H; Steinestel K; Wardelmann E; Senninger N; Abdallah Dhayat S
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2419-2431. PubMed ID: 30244390
[TBL] [Abstract][Full Text] [Related]
37. Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2.
Li J; Yang R; Dong Y; Chen M; Wang Y; Wang G
J Exp Clin Cancer Res; 2019 Jan; 38(1):38. PubMed ID: 30691517
[TBL] [Abstract][Full Text] [Related]
38. An endoplasmic reticulum stress-related signature could robustly predict prognosis and closely associate with response to immunotherapy in pancreatic ductal adenocarcinoma.
Liu S; Hu Q; Xie Z; Chen S; Li Y; Quan N; Huang K; Li R; Fang L
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15589-15608. PubMed ID: 37653101
[TBL] [Abstract][Full Text] [Related]
39. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions.
Bararia A; Dey S; Gulati S; Ghatak S; Ghosh S; Banerjee S; Sikdar N
Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):205-217. PubMed ID: 32312637
[TBL] [Abstract][Full Text] [Related]
40. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
